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/~lCAgmun~ Ca~t~!m transplant centa~ de!amine the treatment and lmnm. 
plant ~ status of ~ !  head ~ n t  (HTx) patmnts. We hy+ 
potheslzed ll~l i ~  transplant (~mler I~aClK~ pattet~t~ l~i~ Our local 
oK!an ~mme~ o~amzatmn (OPO) would m~ult in ddtorentmi ntm~ee l 
tmnsp~ntatm~, and cloal~ for status 1 Pa~ 
M~:  HT~ pa~ ~ as uNOS status I from 111/92 to 17.J31~35 
were anah/zed (n = 637). Pat~en~ ~re  compared by transplant center 
Ior age, ~,  e ~  el head faAum, blood type, brutal, moved ~om status 1 
(TM!), use OI mecham(~ ~ (MS), totalwanmg ks! brrm (TWT), and lolal 
status t l.ne (]'ST t) patron!. We pedomted logzspc and mutt]pie regre~smn 
Io+ ~ el trans~am cent~ on II~ numl0er el tranmplants 
and dealhs afte~ 90 days of TStl. 
Resu~.- A totaJ of 265, 96, !00, and 176 pahenls were hsted at each 
transptanl c"e~e~. IAean TSTI1 hm~ wa.~ 3~ : 36 day~, af'id n~_.a~ age 
wasSt ] 12Vt~,. ,~g~1~Ecant d~ffe~e~c'es we~eo4~i41mnad l~etween tTan~ant 
cenlers in etc41ogy of hesd tadure (p = 003). 1aNT (p .: 0.001). TSTt (p 1 
0001), and TM1 (p .  0.001) After a~luslmg for basel!tie dkfferences, the 
transplam cente~ mmamnd a s~;]n~am ~ of ~ansptam (p - O001) 
and death (p . 01(~1) a~ =tr 90 ~ TST1. 
Corzc/usc~" In our local OPO, praclzoe patlem~ between hansplant cen- 
ters Sagnd~canlly affected numbel of t ran~bons  and deall~ at 90 days 
TSTt It remains lobe astal~shed wl~ethe[ ~ represents ~ pallems 
nat~orta,y. 
• • - - •  Weeldly R isk  of  Death While Await ing 
Transplanlat ion: Relationship to Supped 
Requi red 
L.W. Stevenson+ RC Bo~,rge, D.C Nat!el. W Dec. 1: Krauskopf. 
J.B. Young.+ G M Mullen+ O.E. T~man R.J. Rodeheffer. J.K. Kirkhn. Car~ac 
Transplant Research Database (CTRD~: Brigham and Women's Hos~tal. 
Boston. MAL [ :mvers~fy ol Alabama. B+m~ngham. AL. USA 
Backgroe~ + The current system of pnon~ ~mplms a constant risk el death 
w~thm a g~en status, but nsks may change after listing. 
Methods: Weekly mot!aMy for 6 rr~s was determine for 978 pts wdbeut 
dev~-e at listing in the pre-Trans~ant Database and 284 pts from the Heart- 
mate (LVAD) registry. Non-LVAD pts were further d~KJed into Status I. pls 
hsled II but in hospital or on home IV =no!ropes (Status 1.5) and all oft)or II. 
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Resu/ts: Weekly nsk for Status II remained co~=-tant ~t 0.35 ± 0.14% for 
24 wks. LVAD pts had - 10% weekly mortality for 2 wks. declining to 0.75°0 
0.20% nsk after 5 wks. After 2 wks, weekly mortality was highest for Status 
L Status 1.5 pts had mortality comparable to LVAD pts but higher than Status 
II pts. 
Conclusion: By the time most LVAD pts are listed, weekly risk is similar to 
that for pts hospitalized outside ICU*s or on home inotmpes, but intermediate 
between nsk for other Status I and other Status II pts. Pnonty based on 
interval nsks may decrease waiting ILst deaths. 
• PoaHraneplantaf lon Survltml of  Pst lent l  With 
Mlopathl¢ Giant Cell Myocard l t i l  (GCM) Vemut  
uard lomyopMhy (CM) 
LT Coupe,, L J Olden, GJ Berry, H Tazelaar Mayo C#r~., Rocr~te~ 
MN, USA 
~'gk~'Ou~: Pub!isheq data §~t  suf~qval of paints t ra~nte~ for 
acute mvocardd=s i  wors~ than su~tval of ~ t f a ~  Io~ ca~ 
dmmyooathy. We ~ought o last the hypotho~m that patient= ~ GCM have 
a worse posHransldanl~t~ suP.wal than t;ml~nt~ ffafl~,nta~ fo~ CMr W~ 
~emlfmd 38 pat~ts lf0~ II~ Mtdl~n~T O,t~m Cell Myo~s 
who underwent rar~p!~flMt~t (TX) an() o~mpafe~ eunfl~l to !24 patents 
lransphtnted for CM at ,',~f instit~fJOr~, 
Re~p/fs: M~an age at ffansplantabon o! the GCM and CM groups were 
412 * 113 yearn and 486 r 145 y~a~ (Sft~eflt's T last, p = 0.004), 
and they were 53% and 19% female (¢11t square, p = 0.001). Kaplan.Mokl~ 
sulvwal was B8% and 71% at 5 ye~m fo~, ~ CM as¢l GCM gfou4~ (Fig 
1) U~vanata anah~s t~sing the Iog~ank ~ demonstrated wome survival 
in lhe GCM group (p = 0017~_) M.~vanata ana~yms ~mO a Cox model 
ndlusted for age ~nd gef~er suggeste~ that the survival was still worse m 
the GCM group (p = O03t. RR 2.66. CI 1 05-676) 
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Conclus+on Sutural =s worse m patmnts l ran~Inted for CICM Ihan 
m patents transplanted for CM at our ~nshtutmn; However, most deaths 
occuwnd m the first 30 clays postoperalwely and post-TX GCM sunnval Is 
cornpara.l~le to suP,(Nal in pubhslled TX reds!ties TX is an effective therapy 
for GCM 
~ L o n g  Effect iveness of Heart Term Urgent 
Transplantat ion (HTx)  Compared With Elect ive 
,'4Tx 
E GrendeL M. Fngeno, M Mangmvaccht. E '.rP, ah, F. Olwa, B. Andreuz~, 
G Comeno. G Masoncco, A+P Bares1. P+ Bart~en ~ , A. Pellegrini. "A. De 
Ga.spm'rrs" Camtm¢ Surgen/ and Card~,ogy Center, Heart Failure and 
C.ar#lac TrarTsplant Program. Nlguaro~ Ca' Gmnda h~l .  M#an. llaly: 
f Institute of Bcstatrstlcs. Utm/e~ of Milan. Italy 
Backgrouz~: WhereaS aftentmn has been focused on the influence of preop- 
eralzve status on early sunnval after HTx+ kltle m known about the possdde 
long term Tnpact el urgent versus electn~ HTx. 
Methods- In 500 patmnts (pts) w~ severe CHF referred 1o our Center 
for ellglbdity for HTx (median follow up 45 mor~ls), sunnval was compared 
among pts rnamtaWned on optimal medical therapy (n = 287)+ pls who under- 
went HTx (n = 151). and pts ftsted for HTx but not transplanted (n = 62). In 
the group of pts that underwent HTx. long term sunnval was also compared 
between 10is undergefng electwe HTx (status 2: n = 95) and urgent HTx 
(status 1: n=56] 
Resufts: The proporhOn~ of pts SUntiving at the end of follow up were 
-C% in ~ fitted pts. 88% tn transplanted pts and 44% in listed and not 
transplanted pts. Cumulatw, probabdity of surmval was 97% at I. 2 and 
3 years after etectpve I-IT ~, ~.~ 3~,o. 94% and 7~+ at 1. 2 and 3 years 
respectwely in status 1 rectp.,~nts; at tl~e end el follow up 95=;= vs 78% of 
pts transplanted are still ahv~ ~p - 0.001). Oiscnminant analysis revealed 
that pts who underwent urger,: HTx had higher capillary wedge pressure 
(26.3 ± 9.0 vs 24.3 ± 12.8 mm Hg), higher bilirubin (2,65 ± 3.38 v,~ 1.70 ± 
1.69 mg/dl) and lower sodium (126 ± 6 vs 130 ± 5 mEq~). No statistically 
significant differences were detected regarding mean isc'nemic t~me (135.0 
483 vs 132.8 ± 52.5 minutes) and mean donor age (33.5 ± 12.3 vs 29.8 
± 13.3 years) between the two groups, 
Comments: The long term suwivat of non-refractory CHF pts treated with 
optimal medical therapy is comparable with long term survival of refraCtOry 
CHF pts treated with HTx. In status 1 candidates long tetra sunnval appeared 
